The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis-Reference-Cited by-同舟云学术

The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

Published:2009-09 Issue:9 Volume:33 Page:1199-1203
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Mesa Ruben A.,Schwager Susan,Radia Deepti,Cheville Andrea,Hussein Kebede,Niblack Joyce,Pardanani Animesh D.,Steensma David P.,Litzow Mark R.,Rivera Candido E.,Camoriano John,Verstovsek Srdan,Sloan Jeffrey,Harrison Claire,Kantarjian Hagop,Tefferi Ayalew

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference6 articles.

1. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients;Mesa;Cancer,2007

2. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials;Pardanani;Leukemia,2008

3. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory;Mendoza;Cancer,1999

4. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress;Portenoy;Eur J Cancer,1994

5. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory;Cleeland;Cancer,2000

Cited by 185 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial;The Lancet Haematology;2024-09

2. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis;Blood Advances;2024-08-28

3. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera;Journal of Clinical Medicine;2024-08-22

4. SOHO State of the Art Updates and Next Questions | Measuring Patient-Reported Outcomes (PROs) and Treatment Tolerability in Patients With Hematologic Malignancies;Clinical Lymphoma Myeloma and Leukemia;2024-08

5. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial;Leukemia & Lymphoma;2024-06-05